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ABSTRACT
Osteosarcoma (OS) is the most common bone sarcoma in adolescents, and 
has poor prognosis. A vicious cycle is established between OS cells and their 
microenvironment in order to facilitate the tumor growth and cell spreading. The 
present work aims to better characterize the tumor microenvironment in OS in order 
to identify new therapeutic targets relating to metastatic process. Tissue microarrays 
of pre-chemotherapy OS biopsies were used for characterizing the tumor niche 
by immunohistochemistry. Parameters studies included: immune cells (M1, M2-
subtypes of tumor-associated macrophages (TAM); T, B lymphocytes; mast cells), 
vascularization (endothelial, perivascular cells), OPG, RANKL, and mitotic index. Two 
groups of patients were defined, 22 localized OS (OS Meta-) and 28 metastatic OS 
(OS Meta+). The OS Meta- group was characterized by a higher infiltration of INOS+ 
M1-polarized macrophages and upregulated OPG immunostaining. OS Meta+ tumors 
showed a significant increase in CD146+ cells. INOS+ M1-macrophages were correlated 
with OPG staining, and negatively with the presence of metastases. CD163+ M2-
macrophages were positively correlated with CD146+ cells. In multivariate analysis, 
INOS and OPG were predictive factors for metastasis. An older age, non-metastatic 
tumor, good response to chemotherapy, and higher macrophage infiltration were 
significantly associated with better overall survival. TAMs are associated with better 
overall survival and a dysregulation of M1/M2 polarized-macrophages in favor of M1 
subtype was observed in non-metastatic OS.
INTRODUCTION
Primary bone sarcomas are rare oncologic subtypes, 
accounting for less than 0.2% of the malignant tumors 
registered in the EUROCARE database [1]. These tumors 
are made up of a large number of distinct histological 
entities, especially osteosarcoma (OS), chondrosarcoma 
and Ewing sarcoma originating from mesenchymal 
stem cells [2, 3]. OS is the most common bone sarcoma 
in young patients with a peak of incidence at 18 years. 
Secondary OS occurs in the elderly mainly after Paget 
disease or radiotherapy. The standard treatment involves 
both surgery and chemotherapy, but is unfortunately 
ineffective in many cases, due to the development of 
drug refractory and/or resistance cells, leading to the 
development of metastasis and death. Radiotherapy may 
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be used in palliation [1]. Consequently, OS still has a poor 
prognosis and patient survival is strongly associated with 
the tumor cell response to chemotherapy, and metastatic 
status. A 5-year survival rate of 70% is observed for 
patients with non-metastatic OS, and 30% for patients with 
metastatic OS at diagnosis are still alive at the end of the 
five-year period [4]. Understanding the pathophysiology 
of OS and the metastatic process is a pre-requisite for 
future improvement in therapeutic approaches.
The pathogenesis of OS is closely related to the 
microenvironment in which the tumor grows. Even if 
the etiology of OS has not been clearly established, its 
development has the special feature of being strongly 
associated with its microenvironment and, more 
specifically, with the bone niche. There is effectively 
dysregulation in the balance between Osteoprotegerin 
(OPG) / Receptor Activator of NF-κB (RANK) / RANK 
Ligand (RANKL), provoking exacerbated local bone 
remodeling. As a result, numerous factors initially 
trapped in this matrix are released, which in turn stimulate 
sarcoma cell proliferation, leading to the establishment of 
a vicious cycle between bone and tumor cells [5]. These 
events are associated with early and late events in the 
metastatic process by promoting the neoangiogenesis and 
extravasation of tumor cells [6, 7]. The sarcoma tumor 
niche, as with hematologic disorders, is also considered 
to be a sanctuary for tumor cell expansion, and drug 
resistance leading to cell dissemination [8-10]. 
The immune niche, with its huge cell diversity 
including more specifically tumor-infiltrating lymphocytes 
and tumor-associated macrophages (TAMs), regulates 
the OS microenvironment [11, 12]. TAMs exert 
different effects on tumor development because of their 
polarization. In oncology, M1-polarized macrophages are 
considered to be anti-tumor effectors and M2-polarized 
macrophages are defined as pro-tumor modulators as they 
increase the neoangiogenic process [13-15]. The density of 
TAMs is correlated with tumor cell proliferation, invasion, 
metastasis, and poor prognosis in various epithelial and 
hematological cancers, and in bone metastases [16]. 
The tumour microenvironment is suspected to 
play a regulatory function of OS cells and could be a 
potential source of therapeutic targets, unfortunately its 
characterization has not been very well documented [17, 
18]. In this context, the aim of the present work was to 
characterize the tumor “niche” of localized and metastatic 
human OS by means of histopathological assessment 
in a large biological cohort associated with clinical 
annotations. The final goal was to identify new prognostic 
information in OS, and to specify therapeutic targets.
RESULTS
Patient characteristics and tumor features
Between 1994 and 2013, 159 patients treated for OS 
were identified in the database of the Nantes University 
Hospital (123 patients without metastasis, and 36 with 
metastatic disease). Twenty-two patients without available 
pre-chemotherapy samples were excluded (16 OS Meta- 
and 6 OS Meta+) and 13 patients whose diagnosis 
changed following surgical resection of the specimen or 
reviewing the slides (11 OS Meta-, 2 OS Meta+). For 
the OS Meta- group, 40 patients diagnosed after 2008, 
11 patients with recurrence, 17 with metastatic evolution 
with no available samples, and 6 without follow-up were 
excluded. At the end of the selective process, 22 and 
28 patients were finally included in the OS Meta- and 
OS Meta+ populations respectively. The demographic, 
clinical and histological data of these 50 patients are 
shown in Table I. The median age at diagnosis was similar 
between the two groups (22.5 for OS Meta-, 23.7 for OS 
Meta+). Tumor location (metaphysis of a long bone) and 
the distribution of histological subtypes (conventional OS 
including osteoblastic, chondroblastic and fibroblastic OS) 
were also similar between the two groups. The number 
of male and female patients was similar in the OS Meta- 
group, and males were predominant in the OS Meta+ 
group (19/9). Metastatic lesions were metachronous in 
72% of the cases and the main metastatic site was the lung 
(75%). The survival rate was significantly higher in the OS 
Meta- group (p = 0.0003).
The immune infiltrate of OS Meta- is enriched 
with M1-polarized macrophages compared to OS 
Meta+: relationship with the metastatic process
As immune cells are associated with control of the 
oncogenic process, we first characterized the immune 
infiltrate in OS samples selected by immunohistochemistry 
(Table 2). T and B lymphocyte infiltration were moderately 
detected in all samples studied and were not significantly 
different between the two OS groups. T lymphocytes were 
organized in clusters in contrast to the B lymphocyte 
population which was scattered throughout tumor tissues 
(Supplementary Figure 1). Immune infiltrate was also 
composed of a limited number of mast cells identified 
by the CD117 antibody, with thin granular cytoplasmic 
staining (Supplementary Figure 1). 
TAMs have been shown to control numerous 
biological processes such as cancer cell growth, 
neoangiogenesis and activation of T lymphocytes. We 
thus analyzed TAM infiltration in OS samples (Table 
2 and Figure 1). TAMs were frequently located around 
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Figure 1: Representative immunohistochemical results of CD68, INOS, CD146 and OPG, in primary lesions of OS 
Meta- and OS Meta+. The immunohistochemical study was performed on tissue micro-arrays and analyzed on digitized images. 
Macrophages are the main cells in the bone niche; the qualitatively analysis revealed their perivascular location (Bar scale 250 and 50 
µm, original magnification x10 and x40 respectively). Quantitative analysis showed a significantly higher infiltration of M1-polarized 
macrophages in OS Meta- patients [number of INOS+ cells for 1 high power (x40) microscopic field (HPF) estimated on 3 “hot-spots”; 
median value symbolized with a horizontal bar] (Fisher test, p = 0.001). On the contrary, OS Meta+ had a significantly higher vascular 
density (CD146 staining) (Wilcoxon test, p = 0.014) and OPG density was significantly higher in the OS Meta- group (Wilcoxon test, p 
= 0.028). (Semi-quantitative analysis of vascular or cellular density: 0, no staining; 1, < 1/3 of the surface; 2, between 1/3 and 2/3 of the 
surface; 3, >2/3 of the tumor surface). OS Meta-: patients with non-metastatic OS; OS Meta+: patients with metastatic OS
Oncotarget4www.impactjournals.com/oncotarget
the blood vessels (Figure 1). While the total number of 
CD68 macrophages was similar in both OS populations, 
a differential polarization of these macrophages was 
observed (Table 2). Interestingly, the number of M1-
polarized macrophages (INOS +) was higher in OS 
Meta- compared to OS Meta+ (p = 0.001) (Table 2 and 
Figure 1). In addition, in multivariate analyses, INOS 
was a predictive factor for OS Meta- (p = 0.0298) 
(Supplementary Table 2).
Vascular density is higher in OS Meta+ compared 
to OS Meta- in contrast to OPG expression
The metastatic process is strongly associated 
with neovascularization. Vasculature markers were 
thus studied in the OS samples (Table 2 and Figure 1). 
In contrast to CD31 and SMA immunopositivity, which 
were similar in both OS groups, CD146 was higher in 
the OS Meta+ population compared to OS Meta- (Figure 
1, p = 0.014). This higher vascular density was in favor 
of an upmodulation of the neoangiogenic process. We 
then analyzed OPG expression, a key modulator for 
bone resorption, immune and vascular cells [19]. OPG 
was overexpressed in the OS Meta- group compared to 
Table 1: Characteristics of osteosarcoma patients included in the study
OS Meta-  (n=22) OS Meta+ (n=28) p
Age, mean (years), (min-max) 22.52 (7-76) 23.70 (8-80) 0.7616
Sexe, n (%)
Female
Male
11 (50)
11 (50)
9 (32)
19 (68) 0.2514
Primary tumor site, n (%)
Femur
Tibia/ fibulae
Humerus
Ulna
Others
11 (50)
5 (22,5)
5 (22,5)
1 (5)
0
17 (61)
6 (21)
3 (11)
0
2 (7)
0.6292
Size, mean (cm), (min-max) 9.51 (3-26.5) 11.2 (4.8-31) 0.2143
Histological subtype, n (%)
Fibroblastic
Osteoblastic
Chondroblastic
Composite
Telangiectatic
Parosteal
Secondary
5 (20)
11 (50)
2 (10)
0
1 (5)
2 (10)
1 (5)
7 (25)
13 (46)
3 (10.5)
3 (10.5)
1 (4)
0
1 (4)
0.6887
Neo-adjuvant chemotherapy, n (%) 19 (86) 26 (93) 0.3849
Histological response to chemotherapy, n (%)
I
II
III
4 (22)
5 (28)
9 (50)
8 (31)
8 (31)
10 (38)
0.7381
Soft tissue invasion, n (%) 17 (77) 26 (93) 0.2171
Quality of resection, n (%)
R0
R1
20 (91)
2 (9)
22 (79)
6 (21)
0.4391
Metastases, n (%)
Synchronous
Metachronous
- 8 (28)
20 (72)
Metastatic location, n (%)
Lung
Bone
Lymph Node
Multiple
-
21 (75)
3 (10.5)
1 (4)
3 (10.5)
Size, mean (cm), (min-max) - 3 (0.4-9)
Quality of resection, n (%)
R0
R1
- 21 (95.5)
1 (4.5)
Death, n (%) 2 (9) 20 (71) <0.005
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the OS Meta+ population, and was mainly expressed by 
OS cells (Figure 1, p = 0.028). In multivariate analyses, 
OPG was a predictive factor for OS Meta- (p = 0.0367) 
(Supplementary Table 2).
Correlation study between the various biomarkers 
in the OS niche
The correlation analysis between the biological 
markers in the OS niche revealed various significant 
relationships (Table 3). Macrophage markers were 
positively correlated to each other (INOS/CD68 Spearman 
coefficient SC = 0.599 p < 0.0001, CD68/CD163 SC = 
0.587 p < 0.0001, CD163/INOS SC = 0.451 p = 0.00113). 
In addition, a significant correlation was observed with 
INOS+ M1-macrophages and with CD3+ and CD8+ 
T lymphocyte markers (SC = 0.445, p = 0.00151) 
(Figures 2A), with mast cells (SC = 0.403 p = 0.00407) 
(Supplementary Figure 1A), with OPG staining (SC 
= 0.308, p = 0.03131) (Figure 2A) and RANKL (SC = 
0.345, p = 0.01503) (Figure 2A). Interestingly, INOS+ M1-
macrophages were negatively correlated with the presence 
of metastasis (OR = 0.736, p = 0.01926) (Table III), while 
they correlated positively with the Ki-67 mitotic index 
(SC = 0.428, p = 0.00218) (Figure 2A). CD163+ M2-
macrophages were correlated with CD146+ vascular cells 
(SC = 0.341, p = 0.01543) (Figure 2A). 
Figure 2: INOS+ M1-polarized macrophages correlate CD3+ CD8+ lymphocytes, OPG, RANKL and the mitotic index 
and M2-polarized macrophage with the vascularization in primary lesions of OS. A. A positive correlation was found 
between INOS+ M1-polarized macrophages and CD3+CD8+ lymphocytes, OPG, RANKL and the mitotic index (Spearman correlation, p = 
0.00151, p = 0.03131, p = 0.0150, p = 0.00218 respectively). M2-polarized macrophages as determined by CD163+ cells, were correlated 
with vascularity as determined by CD146+ cell density (Spearman correlation, p = 0.00154). Kaplan-Meier Curve of survival, according 
to presence of metastasis at diagnosis, and of response to chemotherapy: B. Median overall survival was 5.12 years (95%CI: 4.62-7.12). 
C. Patients with metastasis (synchronous or metachronous) were associated with significantly lower median overall survival [3.26 years 
(95%CI: 3.78-7.18)], p < 0.001. D. Patients with a worse histological response to chemotherapy [defined as < 90% of tumor necrosis after 
neoadjuvant chemotherapy] were associated with worse overall survival [4.61 years (95%CI: 3.78-7.18)], p < 0.01. Meta-: non-metastatic 
patients; Meta+: metastatic patients; Grade III, I-II according the Huvos score. 
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The mitotic index was also correlated with CD3+ 
T lymphocytes (CS = 0.383, p = 0.00664), and CD31+ 
vascular cells (SC = 0.324, p = 0.02181). Each vascular 
marker was positively correlated (CD31/SMA SC = 0.368 
p = 0.00858; SMA/CD146 SC = 0.385 p = 0.00581; 
CD146/CD31 SC = 0.408 p = 0.00327). CD146+ cells 
were correlated with T lymphocytes CD3+ (CS = 0.282, 
p = 0.04939) (Table 3). Finally, a positive correlation 
was found between OPG and RANKL (SC = 0.522, p = 
0.0001), and between OPG and mast cells (SC = 0.334, p 
= 0.01765) (Supplementary Figure 1B).
Clinical and biological/histological factors 
associated with survival
The median overall survival for all patients was 
5.12 years (95% IC: 4.62-7.12) (Figure 2B). Oldest age 
at diagnosis is significantly associated with better overall 
survival (p < 0.0001) as well as a non-metastatic status 
(grade III-IV, Huvos score) [6.90 years (95% IC: 6.06-
10.27) vs 3.26 years (95% IC: 2.84-5.31); p = 0.000903 
respectively](Figure 2C). As expected, a good response 
to chemotherapy was also associated with a significant 
survival rate respectively and [5.72 years (95%IC: 4.46-
8.5) vs 4.61 years (95%IC: 3.78-7.18), (p = 0.00702)] 
(Figure 2D). Among the histological markers in primary 
tumors, a higher macrophage infiltration tumor was 
Table 2: Immunohistochemical analysis of osteosarcomas
Antigen studied OS Meta- (n = 22) OS Meta+ (n = 28) p
CD3* median (min-max) 2.3 (0-40) 2 (0-14) 0.510
CD20* median (min-max) 0 (0-3.6) 0 (0-2.6) 0.528
CD4* median (min-max) 0 (0-1.6) 0 (0-4) 0.894
CD8* median (min-max) 3 (0-22) 1.83 (0-19.6) 0.188
CD68* median (min-max) 28.5 (1.5-84.6) 19.3 (5.5-71.3) 0.148
INOS* median (min-max) 3 (0-47) 0 (0-8) 0.001
CD163* median (min-max) 1.2 (0-55) 0.5 (0-8.3) 0.265
CD117* median (min-max) 1 (0-7.3) 0.6 (0-5) 0.15
Ki-67** median (min-max) 3.2 (0-63.3) 1.7 (0-40) 0.379
CD31*** n (%)
Density score 0
1
2
3
5 (22.5)
12 (55)
5 (22.5)
0 (0)
7 (25)
7 (25)
11 (39)
3 (11)
0.108
SMA*** n (%)
Density score 0 
1
2
3
1 (5)
17 (77)
4 (18)
0 (0)
1 (3.5)
21(75)
5 (18)
1 (3.5)
1
CD146*** n (%)
Density score 0
1
2
3
0 (0)
19 (86.4)
3 (13.6)
0 (0)
2 (7.1)
13 (46.5)
11 (39.3)
2 (7.1)
0.014
OPG*** n (%)
Density score 0
 1
 2
 3
1 (4.5)
1 (4.5)
5 (23)
15 (68)
0 (0)
10 (36)
5 (18)
13 (46)
0.028
RANKL*** n (%)
Density score 0
 1
 2
 3
0 (0)
1 (4.5)
6 (27.5)
15 (68)
0 (0)
7 (25)
8 (29)
13 (46)
0.130
OS Meta- : patients with non metastatic osteosarcoma; OS Meta+: patients with metastatic osteosarcoma. * Number of 
cytoplasmic stained cells for 1 high power(x40) microscopic field (HPF) estimated on 3 « hot-spots ». ** Number of stained 
nuclear on one HPF. *** Semi-quantitatively analysis of the vascular or cellular density (0, no staining; 1, < 1/3 of the surface; 
2, between 1/3 and 2/3 of the surface; 3, >2/3 of the tumor surface).
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significantly associated with better overall survival (p = 
0.04609) (Supplementary Table 3).
DISCUSSION
In the absence of any clear etiology for OS, the 
concept of tumor niche has emerged based on the seed 
and soil theory proposed by Paget at the end of the 19th 
century [20, 21]. The tumor niche is defined as a specific 
microenvironment promoting the emergence of cancer-
initiating cells, and providing all the factors required for 
their quiescence, proliferation and migration. A favorable 
tumor niche associated with one or more oncogenic events 
may thus explain the pathogenesis of OS. The present 
work aimed to better characterize the microenvironment 
of OS by comparing non-metastatic and metastatic OS. 
Our study demonstrated a differential composition of the 
tumor niche between the OS Meta- and OS Meta+ groups. 
A significant increase in M1-polarized macrophage 
infiltration and OPG immunostaining was observed in 
OS Meta- compared to OS Meta+. In contrast, OS Meta+ 
exhibited a significantly higher vascular density compared 
to the OS Meta- group. Based on these observations, 
INOS and OPG were identified as predictive factors for 
non-metastatic disease in multivariate analyses. These 
results might make possible better understanding of the 
pathophysiology of OS, and may lead to new therapeutic 
options (e.g. stimulation of the differentiation of TAM 
toward M1 macrophages and/or recruitment of M1 
macrophages). 
In the immune cell population, macrophages are 
the most numerous in the OS tumor niche, regardless 
of the metastatic status of the patients. The exact role 
of macrophages in OS is still unclear and controversial. 
Some studies have defined TAMs as anti-tumoral 
effectors. Buddingh et al. thus demonstrated that higher 
TAM infiltration was associated with better overall 
survival in high-grade OS [22]. However, the authors 
did not observe any differences between metastatic and 
non-metastatic OS, and TAMs exhibited both M1 and 
M2 characteristics [22]. On the contrary, the impact 
of macrophages in tumor development has been also 
suspected. Lewis and Pollard distinguished the anti-
tumor M1-macrophages from M2-macrophages leading 
to tumor growth and invasion, angiogenesis, metastasis 
and immune-suppression [14]. In our study, both INOS 
(M1-polarized macrophage markers) and CD163 (M2-
polarized macrophage markers) were correlated with the 
mitotic index, suggesting the distinct involvement of M1- 
and M2- macrophages in tumor growth. OS development 
Figure 3: Flow chart of inclusion/exclusion criteria. 159 patients were enrolled and after the selective process two groups of 
patients were defined: 22 non-metastatic patients “OS Meta- group”, and 28 metastatic patients, “OS Meta+ group”.
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may thus be accompanied by a switch in the phenotype of 
infiltrating TAMs, from anti-metastatic M1-macrophages 
to pro-metastatic M2-macrophages. This hypothesis is 
in agreement with the in vivo work described by Xiao et 
al. who showed a switch in macrophage subpopulations 
in a mouse model of human OS from M1-macrophages 
during the first week of tumor growth, to M2-macrophages 
after 2-3 weeks [23]. In addition, Pahl et al. demonstrated 
that human M1-like macrophages can be induced to exert 
direct anti-tumor activity against OS cells, mediated by 
TNF-α and IL1-β [24]. In the same manner, Ségaliny et al. 
demonstrated that OS cells expressed IL-34, increasing the 
recruitment of M2-polarized macrophages into the tumor 
tissue, which correlates with tumor vascularization and the 
metastatic process [25]. Our study provides new evidence 
of the dynamic of macrophage differentiation in the OS 
microenvironment.
Regarding the metastatic process, our results 
showed a significantly higher vascular density in OS 
Meta+ and a correlation between M2-macrophages and 
the CD146+ vascular network, providing explanations 
regarding tumor growth and the metastatic process. OS 
cells themselves induce endothelial cell proliferation 
and neoangiogenesis 26, 27]. The close relationship 
between hypoxia, TAMs and vascularization is well-
known in other cancer types reviewed in many studies 
[28-30]. The hypoxic OS microenvironment leads to an 
increase in chemoattractant agents, including HIF-1α 
(transcription factor for pro-angiogenic factors such as 
VEGF) and CXCL12 expressed by myeloid cells [31], 
and induces macrophage differentiation preferentially 
toward a M1-macrophage phenotype. In return, TAMs 
play an important role in the angiogenic switch, releasing 
more than 30 cytokines and angiogenic factors, such as 
VEGF, b-FGF, IL-8 and IL-6 [32]. This vascularization 
facilitates the metastatic process, promoting the migration/
circulation of tumor cells, thanks to matrix degradation by 
matrix metalloproteinases (MMP2, MMP7 and MMP9), 
which are released by tumor cells and by TAMs as well [7, 
33]. However, little is known about this direct correlation 
between TAMs and vascular density in human OS samples. 
Ségaliny et al. demonstrated that IL-34 promotes the 
adhesion of mononuclear phagocytes (CD34+/monocytes) 
to activated endothelial cells under physiological shear 
stress conditions [25]. Guo et al. showed that hypoxia 
promoted migration and induced CXCR4 expression via 
HIF-1α activation in human OS [34].
In our study, INOS infiltration and OPG staining 
were significantly higher in OS Meta- and there was a 
positive correlation between M1-polarized macrophages 
and OPG. OPG still plays a controversial role, with 
both pro- and anti-tumor activity in the bone OS 
microenvironment [35]. In the same way, there are some 
conflicting data about the functional relationship between 
osteoclasts and tumor cells. Avnet et al. highlighted 
that the occurrence of osteoclasts in OS biopsies was 
positively associated with aggressive disease (presence 
of lung metastases at diagnosis) [36], whereas the loss of 
osteoclasts contributed to the development of pulmonary 
metastases for other authors [37]. Endo-Munoz et 
al. suggested an evolution in the microenvironment 
during tumor growth: osteoclasts contribute to a niche 
environment in the early stage of OS, nurturing the growth 
and expansion of the tumor, whereas in the later stage 
Table 3: Correlation analysis between the biological markers of osteosarcoma microenvironment
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disease, intra-tumor heterogeneity leads to the acquisition 
of phenotypes that inhibit osteoclastogenesis, and the 
destruction of the niche, thus permitting metastasis [11]. 
All these data underline the importance of distinguishing 
local tumor growth from the metastatic process. According 
to previous studies targeting atheromatous plaques and 
bone formation, the link between macrophages and OPG 
can be explained by the OPG-induced chemotactism of 
M1-macrophages, and in turn, by the secretion of OPG by 
endothelial cells [38-41].
The characterization of the microenvironment 
makes it possible to explain not only tumor growth and 
the metastatic process, but also to propose therapeutics. 
Based on the present study, targeting M2-macrophages 
and blocking their pro-angiogenic activity appears to be an 
interesting therapeutic approach for OS. On the contrary, 
the promotion of M1-macrophages may improve overall 
survival, as is already the case with the macrophage-
activating agent, muramyl tripeptide-phosphatidyl 
ethanolamine (MTP-PE) [24, 42-45]. Finally, several 
preclinical studies show the benefit of targeting the bone 
microenvironment, associated with a better response 
to chemotherapy and a decrease in tumor growth [46-
48]. Our study gives additional arguments for active 
participation of the immune cells, vascularization, and 
bone constituents in response to chemotherapy. Regarding 
overall survival, an older age at diagnosis, non-metastatic 
tumor, good response to chemotherapy and marked TAM 
infiltration were associated with a better prognosis. Older 
age, detectable primary metastases, and tumor necrosis 
after chemotherapy are currently validated as prognostic 
factors, as are large tumor size, and location (axial or 
proximal extremity) [1, 49]. As metastasis decreases 
the diagnosis, we assessed the impact of the prognostic 
factor for metastasis on overall survival. We observed the 
significant prognostic impact of TAM on overall survival 
in OS (whether it is metastatic or not), confirming the data 
of Buddingh et al. [22]. These results, plus the fact that 
INOS infiltration is a predictive factor for a non-metastatic 
process, underline the key role played by TAMs, and their 
associated subtypes, in OS pathophysiology and outcome. 
It has also become necessary to characterize each key 
player in the bone microenvironment at each step/stage 
of tumor development in order to understand the dynamic 
evolution, and to adapt the treatment.
MATERIALS AND METHODS
Patient cohort
Patient data were collected from the pathology 
database at the Nantes University Hospital (France). The 
experimental procedures were carried out in accordance 
with both the ethical standards of the responsible 
institutional committee on human experimentation, and 
with the Helsinki Declaration (Authorization: French 
Research Ministry n° 2008-402). All patients with OS 
treated between January 01, 1994 and January 01, 2013, 
for whom paraffin-embedded tissue blocks of primary 
tumors were available, were included. The inclusion and 
exclusion criteria are summarized in Figure 3. Patients 
without pre-chemotherapy samples (diagnosis made in 
another center or in resection specimens) and patients 
whose diagnosis changed following resection of the 
specimens or reviewing the slides were excluded. For 
non-metastatic patients, those with local recurrence, or 
without follow-up were excluded and a minimum of 5 
years’ follow-up was required. Two cohorts were finally 
formed: patients with non-metastatic OS (OS Meta-
) and patients with metastatic OS (OS Meta+). For all 
patients, the following data were collected retrospectively 
using electronic or paper files, or, if necessary, through 
direct telephone contact with the general practitioner: 
demographic data, tumor location, treatment, metastasis 
(location, synchronous or metachronous) and death (date 
and cause).
Tissue microarray preparation and histological 
analysis
OS tissue samples were formalin-fixed (10%), 
decalcified and paraffin-embedded. Samples were 
decalcified with nitric acid or by electrolysis with 
SAKURA TDETM 30 (Japan) (98% formic acid, 2% 
hydrochloric acid). Four µm sections were obtained and 
stained with hematoxylin eosin saffron (HES). Each 
primary tumor was classified according to the World 
Health Organization (WHO) 2013 classification of 
malignant bone tumors by two independent pathologists 
[50]. The following histological data were collected: i) 
location of the primary tumor; ii) in a surgical specimen 
after neoadjuvant chemotherapy: tumor size, histological 
response after chemotherapy according to the Huvos score 
[grades I, II, III and IV characterized by ≤50%, >50% and 
≤90%, >90% and ≤99%, and 100% of tumor necrosis 
respectively, poor responders with a Huvos score of grades 
I or II, and good responders with grades III or IV] soft 
tissue invasion (size) [51], quality of resection (R0 or R1), 
vascular emboli; iii) metastasis: size, quality of resection 
(R0 or R1). Given how small and precious the tumor 
samples available were, tissue microarrays (TMAs) were 
prepared. Three core samples of 1 mm in diameter were 
performed for each case, in the most representative areas 
of the HES sections, and then included in paraffin blocks. 
Three µm sections were stained with HES and used for 
immunohistochemistry investigations.
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Immunohistochemistry
After systematic optimization of antigen retrieval 
and antigen detection by primary antibody on human 
placenta samples decalcified with nitric acid or 
electrolysis, the following antigens were studied: CD68, 
pan-macrophages; INOS, M1-macrophage subtype; 
CD163, M2-macrophage subtype; CD3, CD4 and CD8, 
T lymphocytes; CD20, B lymphocytes; CD117, mast 
cells; CD31, CD146, and smooth muscle actin (SMA) 
for endothelial and perivascular cells; OPG; RANKL 
and MIB-1 (Ki-67 index) (Supplementary Table 1). 
CD3, CD4, CD8, CD20, CD68, CD117, SMA, CD31 
and Ki-67 antigen were detected using a fully automated 
immunohistochemical device (DAKO Autostainer 
Link 48) associated with the Dako EnVisionTM Flex 
detection system. Immunoreactivity was detected 
by DakoEnVisionTM FLEX DAB+ Chromogen. The 
immunoreactivity of CD146, INOS, OPG and RANKL 
were analyzed using a manual technical process. 
After deparaffinization and rehydration of the tissue 
sections, antigen retrieval was carried out at 96°C 
for 20 h in EDTA or citrate buffer (LabVisionTM PT 
Module, ThermoScientific). Endogenous peroxidase was 
blocked with hydrogen peroxide followed by blocking 
the non-specific antibody. Then, the corresponding 
primary antibody was deposited, antigen positivity was 
revealed with DAB chromogen and tumor sections were 
counterstained with hematoxylin. The negative control was 
analyzed using a similar procedure, excluding the primary 
antibody and using a normal rabbit-irrelevant IgG (R&D 
Systems). TMAs slides were scanned and the images 
were automatically digitized (Nanozoomer, Hamamatsu 
photonics) before quantification. Immunoreactivity 
was analyzed qualitatively (cell type, location, nuclear / 
membrane / cytoplasmic staining) and semi-quantitatively. 
Semi-quantification was done according to the following 
criteria: i) for the immune cells: number of cytoplasmic 
stains on 3 high power (x40) microscopic fields (HPF) 
in “hot-spots” (areas with high cellular density) per core 
sample; ii) for vascular, tumor cell density and OPG/
RANKL positivity: 0, no staining; 1, < 1/3 of the surface; 
2, between 1/3 and 2/3 of the surface; 3, > 2/3 of the 
surface; iii) for tumor cell proliferation: number of MIB-1 
nuclear stains on one HPF. For each case, the mean of the 
values in the three core samples was performed, and the 
higher value for vascular or cellular density was selected. 
For observations and semi-quantifications, a double-blind 
examination by two experienced pathologists was carried 
out.
Statistical analysis
Categorical data were presented as numbers 
and frequencies and quantitative data were presented 
with their median and range. To test the link with the 
presence of metastases, a non-parametric Fisher’s test 
was used for categorical data and a non-parametric Mann-
Whitney Wilcoxon’s test for quantitative and gradual 
data. Spearman’s correlation coefficient was computed 
to compare variables in pairs for primary lesions. The 
Odds ratio was computed to compare quantitative and 
qualitative variables in pairs for primary lesions. A 
multivariate logistic regression analysis was used to 
study the relationship between different variables and the 
presence of metastases. A Cox model was also used to test 
the relationship between different variables and patient 
survival time. Data with missing values were excluded 
from the statistical analysis. An alpha level of 0.05 was 
chosen to assess statistical significance. All statistics were 
performed using R 3.1.0 software.
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